Search

Your search keyword '"Manez R"' showing total 7 results
Start Over Author "Manez R" Topic humans
7 results on '"Manez R"'

1. Perceived differences between intensivists and infectious diseases consultants facing antimicrobial resistance: a global cross-sectional survey

Author

Abravci, N., Hobrok, M., Felton, T., Fletcher, S., Marshall, B., McConnell, H., Mckee, R., McAuley, D., Mcfie, C., Morton, B., Naisbitt, J., Rooney, K., Szakmany, T., Yates, B., Zochios, V, Wunderink, Richard G., Von der Osten, J., Rello, Jordi, Eshwara, Vandana Kalwaje, Conway-Morris, Andrew, Lagunes, Leonel, Alves, Joana, Alp, Emine, Zhang, Zhongheng, Mer, Mervyn, Luna, C. M., Reina, R., Dobrevska, R., Deng, H., Leiqing, L., Liu, L., Wang, D., Yuetian, Y., Zhang, G., Zhang, Zh, Zheng, C., Del Rio, G., Rojas, J. N., Amare, D., Alfandri, S., Argemi, X., Kernies, S., Lesprit, P., Arvanitik, K., Papanikolaou, M., Tsigou, E., Soultati, I, Platsouka, E., Katsiari, M., Nikolaou, C., Tsiodras, S., Antonelli, M., Cascio, A., Dellamonica, J., DiPascale, G., Garofalo, E., Girardis, M., Leone, D., Vandana, K. E., Kaniyarakkal, V, Munim, F., Nath, S., Patil, S., Suchitra, U., Yahav, D., Misango, D. O., Gecaj-Gashi, A., Rotimi, V, Aguilar, D., Araujo-Melendez, J., Franco-Zendejas, R., Lagunes, L., Lemus, J., Martinez D E, Perales, Chavez M, Rivera, Schouten, J., Khamis, F., Nizamuddin, S., Santos, L., Santos-Ribeiro, E., Alekar, S., Baker, D., Ballot, D., Black, V, Bhamjee, S., Brannigan, L., Hunt, I. A., Kotze, J., Lowman, W., Levy, B., Mer, M., Morar, R., Michell, W., Nana, T., Pahad, H., Tsai, M., Schleicher, G. K., Shaddock, E., Shoul, E., Smith, C., Richards, G. A., Van der Merwe, L., Welkovics, N., Borges, M., Diaz, E., Garnacho-Montero, J., Maseda, E., Manez, R., Rello, J., Samso, E., Serrano, R., Sole-Violan, J., Vidaur, L., Zaragoza, R., Wongsurakiat, P., Akbudak, I, Akkoyunlu, YASEMİN, Altindis, M., DCelebi, Aydin G., Emel, A., Alp, E., Erdem, H., Gulden, E., Guner, R., Kizmaz, Y., Yalcin, A., Kepenek, E., Sener, A., Tekin, R., Tulek, N., Ulu, Unuvar G., Miftode, E., Buckley, J., Conway-Morris, A., Dunn, M., Hall, A., and AKKOYUNLU, YASEMİN

Subjects
Microbiology (medical), medicine.medical_specialty, Critical Care, Cross-sectional study, Microbial Sensitivity Tests, Global Health, Communicable Diseases, Cohort Studies, Antibiotic resistance, Medical microbiology, Enterobacteriaceae, Drug Resistance, Multiple, Bacterial, Physicians, Anesthesiology, Intensive care, medicine, Humans, Infection control, Infection Control, biology, business.industry, General Medicine, biochemical phenomena, metabolism, and nutrition, bacterial infections and mycoses, biology.organism_classification, a global cross-sectional survey-, EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, cilt.38, ss.1235-1240, 2019 [Rello J., Eshwara V. K. , Conway-Morris A., Lagunes L., Alves J., Alp E., Zhang Z., Mer M., Luna C. M. , Reina R., et al., -Perceived differences between intensivists and infectious diseases consultants facing antimicrobial resistance], Anti-Bacterial Agents, Acinetobacter baumannii, Intensive Care Units, Cross-Sectional Studies, Infectious Diseases, Carbapenems, Infectious disease (medical specialty), Emergency medicine, business
Abstract

To identify differences in perception on multi-drug-resistant (MDR) organisms and their management at intensive care units (ICU). A cross-sectional survey was conducted. A proposal addressing a pathogen priority list (PPL) for ICU, arising from the TOTEM study, was compared with a sample of global experts in infections in critically ill patients. The survey was responded by 129 experts. Globally, ESBL Enterobacteriaceae, followed by carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Klebsiella pneumoniae, were the main concerns. Some differences in opinion were identified between 63 (49%) ICU physicians (ICU/anesthesiology) and 43 (33%) infectious disease consultants (ID physicians/microbiologists). The pathogens most concerning in the ICU for intensivists were ESBL Enterobacteriaceae (38%) versus carbapenem-resistant A. baumannii (48.3%) for ID consultants, (p 0.05). Increasing number of ID consultants over intensivists (26% vs 14%) reported difficulty in choosing initial therapy for carbapenem-resistant A. baumannii. For intensivists, the urgent measures to limit development of antibiotic resistance were headed by cohort measures (26.3%) versus increasing nurse/patient ratio (32.5%) for ID consultants, (p 0.05). Regarding effectiveness to prevent MDR development and spread, education programs (42.4%) were the priority for intensivists versus external consultation (35.7%) for ID consultants. Finally, both groups agreed that carbapenem resistance was the most pressing concern ( 70%) regarding emerging resistance. Differences in priorities regarding organisms, infection control practices, and educational priorities were visualized between ID/clinical microbiologists and ICU/anesthesiologists. Multi-disciplinary collaboration is required to achieve best care for ICU patients with severe infections.

Published
2019
Full Text
View/download PDF

2. Detection of cytomegalovirus in formalin-fixed paraffin-embedded donor, native and allograft liver tissue using a multiplex polymerase chain reaction-liquid hybridization assay

Author

Ps, Randhawa, Jaffe R, Faruki H, Cr, Rinaldo, Ho M, Aj, Demetris, Manez R, Kusne S, and Garth Ehrlich

Subjects
Base Sequence, Liver, DNA, Viral, Molecular Sequence Data, Cytomegalovirus, Humans, Nucleic Acid Hybridization, Polymerase Chain Reaction, Liver Transplantation, Retrospective Studies
Abstract

A multiplex polymerase chain reaction (PCR)-liquid hybridization assay detecting a minimum 10 fg of cytomegaloviral (CMV) DNA has been developed. This assay successfully detected viral nucleic acids in 25/26 (96.2%) routinely embedded allograft liver biopsies with CMV hepatitis. No CMV DNA was detected in 15 native and 12 donor liver tissues sampled at the time of liver transplantation. These results indicate that archived formalin-fixed, paraffin-embedded liver tissues obtained from patients with significant liver disease can be successfully analyzed for CMV by PCR, retrospectively. Failure to detect CMV in native and donor livers implies that any latent virus present within these tissues is very focally distributed, or is below the threshold of detection applicable to PCR.

Published
1994

3. PROSPECTS OF CLINICAL XENOTRANSPLANTATION

Author

Starzl, T. E., Tzakis, A., Fung, J. J., Todo, S., Demetris, A. J., Manez, R., Ignazio Marino, Valdivia, L., and Murase, N.

Subjects
Adult, Liver, Cricetinae, Transplantation, Heterologous, Animals, Humans, Middle Aged, Radionuclide Imaging, Tomography, X-Ray Computed, Complement Activation, Article, Liver Transplantation, Papio

4. Intestinal transplantation and bacterial overgrowth in humans

Author

Abu-Elmagd, K., Todo, S., Tzakis, A., Furukawa, H., Bonet, H., Mohamed, H., Nour, B., Reyes, J., Green, M., Manez, R., Pasculle, W., John Fung, and Starzl, T. E.

Subjects
Enteral Nutrition, Time Factors, Mycoses, Ileum, Intestine, Small, Humans, Parenteral Nutrition, Total, Bacterial Infections, Intestinal Mucosa, Article, Follow-Up Studies, Liver Transplantation, Retrospective Studies

5. Oxidative Stress in Structural Valve Deterioration: A Longitudinal Clinical Study

Author

Galiñanes, Manuel, Casós, Kelly, Blasco-Lucas, Arnau, Permanyer, Eduard, Máñez, Rafael, Le Tourneau, Thierry, Barquinero, Jordi, Schwartz, Simon, Bottio, Tomaso, Roussel, Jean Christian, Fellah-Hebia, Imen, Sénage, Thomas, Evangelista Masip, Arturo, Badano, Luigi P., Ruiz-Majoral, Alejandro, Galli, Cesare, Padler-Karavani, Vered, Soulillou, Jean-Paul, Vidal Guitart, Xavier, Cozzi, Emanuele, Costa, Cristina, Universitat Autònoma de Barcelona, Universitat Autònoma de Barcelona (UAB), Vall d'Hebron University Hospital [Barcelona], Vall d’Hebron Research Institute (VHIR), Llobregat Hospital [Barcelona], Quironsalud Teknon Heart Institute [Barcelona, Spain] (QTHI), Institut d'Investigació Biomèdica de Bellvitge [Barcelone] (IDIBELL), Bellvitge University Hospital [Barcelona, Spain], Centre d'investigation clinique (CIC) de Nantes -CIC Plurithématique (CIC 0004 - Nantes), Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Università degli Studi di Padova = University of Padua (Unipd), Azienda Ospedale Università di Padova = Hospital-University of Padua (AOUP), Centre hospitalier universitaire de Nantes (CHU Nantes), Institut du Thorax [Nantes], Università degli Studi di Milano-Bicocca = University of Milano-Bicocca (UNIMIB), Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione Avantea [Cremona, Italy], Tel Aviv University (TAU), Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology (U1064 Inserm - CR2TI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Institut Català de la Salut [Barcelona, Spain] (ICS), L’Hospitalet de Llobregat [Barcelona, Spain], The project was funded by the European Commission (FP7/2007–2013, Grant Agreement 603049: accessed on 1 September 2013, and PERIS SLT002/16/00445 funded by the Department of Health of the Generalitat de Catalunya, both granted to C.C., and cofunded by FEDER funds, a way to build Europe. IDIBELL benefits from the support of CERCA., European Project: 603049,EC:FP7:HEALTH,FP7-HEALTH-2013-INNOVATION-1,TRANSLINK(2013), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), KERANDEL-DION, Céline, Defining the role of xeno-directed and autoimmune events in patients receiving animal-derived bioprosthetic heart valves - TRANSLINK - - EC:FP7:HEALTH2013-09-01 - 2017-08-31 - 603049 - VALID, Galinanes, M, Casos, K, Blasco-Lucas, A, Permanyer, E, Manez, R, Le Tourneau, T, Barquinero, J, Schwartz, S, Roussel, T, Fellah-Hebia, I, Senage, T, Evangelista, A, Badano, L, Ruiz-Majoral, A, Galli, C, Padler-Karavani, V, Soulillou, J, Vidal, X, Cozzi, E, and Costa, C

Subjects
Estrès oxidatiu, [SDV]Life Sciences [q-bio], Structural valve deterioration, Lipid peroxidation, Prosthesis Design, Biochemistry, structural valve deterioration, aortic valve, biological heart valves, lipid peroxidation, oxidative stress, protein nitration, transcatheter aortic valve implantation, Humans, Aortic valve, Molecular Biology, Heart valve prosthesis, Heart valves, oxidative stre, Transcatheter aortic valve implantation, Pròtesis valvulars cardíaques, MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE, Aortic Valve Stenosis, Vàlvules cardíaques, biological heart valve, Prosthesis Failure, [SDV] Life Sciences [q-bio], Treatment Outcome, Oxidative stress, Heart Valve Prosthesis, Biological heart valves, Protein nitration
Abstract

International audience; The cause of structural valve deterioration (SVD) is unclear. Therefore, we investigated oxidative stress markers in sera from patients with bioprosthetic heart valves (BHVs) and their association with SVD. Blood samples were taken from SVD (Phase A) and BHV patients during the first 24 (Phase B1) and >48 months (Phase B2) after BHV implantation to assess total antioxidant capacity (TAC), malondialdehyde (MDA), and nitrotyrosine (NT). The results show that MDA levels increased significantly 1 month after surgery in all groups but were higher at 6 months only in incipient SVD patients. NT levels increased gradually for the first 24 months after implantation in the BHV group. Patients with transcatheter aortic valve implantation (TAVI) showed even higher levels of stress markers. After >48 months, MDA and NT continued to increase in BHV patients with a further elevation after 60–72 months; however, these levels were significantly lower in the incipient and established SVD groups. In conclusion, oxidative stress may play a significant role in SVD, increasing early after BHV implantation, especially in TAVI cases, and also after 48 months’ follow-up, but decreasing when SVD develops. Oxidative stress potentially represents a target of therapeutic intervention and a biomarker of BHV dysfunction.

Published
2022
Full Text
View/download PDF

6. The role of antibody responses against glycans in bioprosthetic heart valve calcification and deterioration

Author

Thomas Senage, Anu Paul, Thierry Le Tourneau, Imen Fellah-Hebia, Marta Vadori, Salam Bashir, Manuel Galiñanes, Tomaso Bottio, Gino Gerosa, Arturo Evangelista, Luigi P. Badano, Alberto Nassi, Cristina Costa, Galli Cesare, Rizwan A. Manji, Caroline Cueff de Monchy, Nicolas Piriou, Romain Capoulade, Jean-Michel Serfaty, Guillaume Guimbretière, Etienne Dantan, Alejandro Ruiz-Majoral, Guénola Coste du Fou, Shani Leviatan Ben-Arye, Liana Govani, Sharon Yehuda, Shirley Bachar Abramovitch, Ron Amon, Eliran Moshe Reuven, Yafit Atiya-Nasagi, Hai Yu, Laura Iop, Kelly Casós, Sebastián G. Kuguel, Arnau Blasco-Lucas, Eduard Permanyer, Fabrizio Sbraga, Roger Llatjós, Gabriel Moreno-Gonzalez, Melchor Sánchez-Martínez, Michael E. Breimer, Jan Holgersson, Susann Teneberg, Marta Pascual-Gilabert, Alfons Nonell-Canals, Yasuhiro Takeuchi, Xi Chen, Rafael Mañez, Jean-Christian Roussel, Jean-Paul Soulillou, Emanuele Cozzi, Vered Padler-Karavani, unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nantes Université - UFR des Sciences Pharmaceutiques et Biologiques (Nantes Université - UFR Pharmacie), Tel Aviv University (TAU), Brigham & Women’s Hospital [Boston] (BWH), Harvard Medical School [Boston] (HMS), Università degli Studi di Padova = University of Padua (Unipd), Universitat Autònoma de Barcelona (UAB), Vall d'Hebron University Hospital [Barcelona], Università degli Studi di Milano-Bicocca = University of Milano-Bicocca (UNIMIB), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Llobregat Hospital [Barcelona], Fondazione Avantea [Cremona, Italy], St. Boniface Hospital Albrechtsen Research Centre [Winnipeg], Israel Institute for Biological Research (IIBR), University of California [Davis] (UC Davis), University of California (UC), Institut d'Investigació Biomèdica de Bellvitge [Barcelone] (IDIBELL), Quironsalud Teknon Heart Institute [Barcelona, Spain] (QTHI), Mind the Byte [Barcelona, Spain], Molomics [Barcelona, Spain], Sahlgrenska Academy at University of Gothenburg [Göteborg], Institut Universitari de Ciència i Tecnologia [Barcelona, Spain] ((Inkemia Group) IUCT), DevsHealth [Barcelona, Spain] (DH), University College of London [London] (UCL), Bellvitge University Hospital [Barcelona, Spain], Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology (U1064 Inserm - CR2TI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Dantan, Etienne, Senage, T, Paul, A, Le Tourneau, T, Fellah-Hebia, I, Vadori, M, Bashir, S, Galinanes, M, Bottio, T, Gerosa, G, Evangelista, A, Badano, L, Nassi, A, Costa, C, Cesare, G, Manji, R, Cueff de Monchy, C, Piriou, N, Capoulade, R, Serfaty, J, Guimbretiere, G, Dantan, E, Ruiz-Majoral, A, Coste du Fou, G, Leviatan Ben-Arye, S, Govani, L, Yehuda, S, Bachar Abramovitch, S, Amon, R, Reuven, E, Atiya-Nasagi, Y, Yu, H, Iop, L, Casos, K, Kuguel, S, Blasco-Lucas, A, Permanyer, E, Sbraga, F, Llatjos, R, Moreno-Gonzalez, G, Sanchez-Martinez, M, Breimer, M, Holgersson, J, Teneberg, S, Pascual-Gilabert, M, Nonell-Canals, A, Takeuchi, Y, Chen, X, Manez, R, Roussel, J, Soulillou, J, Cozzi, E, Padler-Karavani, V, Institut Català de la Salut, [Senage T] Institut du Thorax, Institut National de la Santé et de la Recherche Médicale UMR1087, University Hospital, Nantes, France. Institut National de la Santé et de la Recherche Médicale UMR 1246-SPHERE, Nantes University, Tours University, Nantes, France. [Paul A] Department of Cell Research and Immunology, Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel. Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA. [Le Tourneau T, Fellah-Hebia I] Institut du Thorax, Institut National de la Santé et de la Recherche Médicale UMR1087, University Hospital, Nantes, France. [Vadori M] Consortium for Research in Organ Transplantation, Ospedale Giustinianeo, Padova, Italy. [Bashir S] Department of Cell Research and Immunology, Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel. [Galiñanes M] Servei de Cirurgia Cardíaca, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Evangelista A] Servei de Cardiologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Casós K] Servei de Cirurgia Cardíaca, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Infectious Diseases and Transplantation Division, Institut d’Investigació Biomèdica de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain. Grup de Recerca en Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Blasco-Lucas A] Servei de Cirurgia Cardíaca, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Cardiac Surgery Department, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain. [Permanyer E] Servei de Cirurgia Cardíaca, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Department of Cardiac Surgery, Quironsalud Teknon Heart Institute, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
[SDV]Life Sciences [q-bio], Immunology, enfermedades cardiovasculares::enfermedades cardíacas [ENFERMEDADES], Cardiovascular, Medical and Health Sciences, General Biochemistry, Genetics and Molecular Biology, Mice, Polysaccharides, Animals, Humans, Prospective Studies, Polysaccharide, Bioprosthesi, Bioprosthesis, 5.3 Medical devices, Animal, Calcinosis, Galactose, Otros calificadores::Otros calificadores::/cirugía [Otros calificadores], MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE, General Medicine, Aortic Valve Stenosis, Aortic Valve Stenosi, Other subheadings::Other subheadings::/surgery [Other subheadings], Vàlvula aòrtica - Cirurgia, [SDV] Life Sciences [q-bio], Cardiovascular Diseases::Heart Diseases [DISEASES], Prospective Studie, Heart Disease, Aortic Valve, Immunoglobulin G, Antibody Formation, Calcinosi, Development of treatments and therapeutic interventions, Immunoglobulines, Human
Abstract

Outcomes research; Risk factors Investigación de resultados; Factores de riesgo Recerca dels resultats; Factors de risc Bioprosthetic heart valves (BHVs) are commonly used to replace severely diseased heart valves but their susceptibility to structural valve degeneration (SVD) limits their use in young patients. We hypothesized that antibodies against immunogenic glycans present on BHVs, particularly antibodies against the xenoantigens galactose-α1,3-galactose (αGal) and N-glycolylneuraminic acid (Neu5Gc), could mediate their deterioration through calcification. We established a large longitudinal prospective international cohort of patients (n = 1668, 34 ± 43 months of follow-up (0.1–182); 4,998 blood samples) to investigate the hemodynamics and immune responses associated with BHVs up to 15 years after aortic valve replacement. Early signs of SVD appeared in

Published
2021
Full Text
View/download PDF

7. Mesoporous Silica-Based Materials with Bactericidal Properties

Author

Aziz Maleki, Félix Sancenón, Ramón Martínez-Máñez, Andrea Bernardos, Raymond J. Turner, Elena Piacenza, Mehrdad Hamidi, Bernardos A., Piacenza E., Sancenon F., Hamidi M., Maleki A., Turner R.J., and Martinez-Manez R.

Subjects
medicine.drug_class, Antibiotics, Nanotechnology, Biocompatible Materials, 02 engineering and technology, Microbial Sensitivity Tests, 010402 general chemistry, Bacterial Physiological Phenomena, 01 natural sciences, antibiotics, Biomaterials, Antibiotic resistance, Drug Delivery Systems, QUIMICA ORGANICA, QUIMICA ANALITICA, medicine, High surface area, Humans, General Materials Science, Controllable drug delivery systems, Settore CHIM/02 - Chimica Fisica, Drug Carriers, controllable drug delivery systems, Bacteria, Chemistry, QUIMICA INORGANICA, Biofilm, General Chemistry, Mesoporous silica, 021001 nanoscience & nanotechnology, Antimicrobial, Silicon Dioxide, 0104 chemical sciences, Anti-Bacterial Agents, Nanostructures, mesoporous silica materials, Biofilms, Drug delivery, Mesoporous silica materials, Surface modification, Nanoparticles, nanoparticles, 0210 nano-technology, Porosity, Biotechnology
Abstract

[EN] Bacterial infections are the main cause of chronic infections and even mortality. In fact, due to extensive use of antibiotics and, then, emergence of antibiotic resistance, treatment of such infections by conventional antibiotics has become a major concern worldwide. One of the promising strategies to treat infection diseases is the use of nanomaterials. Among them, mesoporous silica materials (MSMs) have attracted burgeoning attention due to high surface area, tunable pore/particle size, and easy surface functionalization. This review discusses how one can exploit capacities of MSMs to design and fabricate multifunctional/controllable drug delivery systems (DDSs) to combat bacterial infections. At first, the emergency of bacterial and biofilm resistance toward conventional antimicrobials is described and then how nanoparticles exert their toxic effects upon pathogenic cells is discussed. Next, the main aspects of MSMs (e.g., physicochemical properties, multifunctionality, and biosafety) which one should consider in the design of MSM-based DDSs against bacterial infections are introduced. Finally, a comprehensive analysis of all the papers published dealing with the use of MSMs for delivery of antibacterial chemicals (antimicrobial agents functionalized/adsorbed on mesoporous silica (MS), MS-loaded with antimicrobial agents, gated MS-loaded with antimicrobial agents, MS with metal-based nanoparticles, and MS-loaded with metal ions) is provided., The authors thank the Spanish Government (projects MAT2015-64139-C4-1-R and AGL2015-70235-C2-2-R (MINECO/FEDER)) and the Generalitat Valenciana (project PROMETEOII/2014/047 and PROMETEO/2018/024) for support. A.B. thanks the Spanish Government for her Juan de la Cierva incorporacion contract IJCI-2014-21534.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results